Advertisement
Canada markets open in 3 hours 41 minutes
  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CAD/USD

    0.7312
    +0.0014 (+0.19%)
     
  • CRUDE OIL

    82.70
    -0.11 (-0.13%)
     
  • Bitcoin CAD

    87,347.03
    -3,341.71 (-3.68%)
     
  • CMC Crypto 200

    1,362.73
    -19.84 (-1.43%)
     
  • GOLD FUTURES

    2,338.50
    +0.10 (+0.00%)
     
  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • NASDAQ futures

    17,512.25
    -152.25 (-0.86%)
     
  • VOLATILITY

    16.20
    +0.23 (+1.44%)
     
  • FTSE

    8,086.68
    +46.30 (+0.58%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • CAD/EUR

    0.6814
    -0.0005 (-0.07%)
     

Gilead Sciences: Analysts’ Recommendations

Gilead Sciences: Analysts’ Recommendations

In November, among the 28 analysts covering Gilead Sciences (GILD), six recommended a “strong buy,” ten recommended a “buy,” and 12 recommended a “hold.” The mean rating for Gilead Sciences stock is 2.21 with a target price of $86.15, which implies an upside potential of 22.5% over Gilead Sciences’ closing price of $70.31 on November 1.